In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...

Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

The medical community is now utilizing minimal residual disease (MRD) testing, which can detect a single cancer cell among a ...

All 20 smoldering myeloma patients had deep responses after one-time infusion ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in multiple myeloma by guiding personalized treatment intensity, potentially ...

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...

Results showed the minimal residual disease negativity rate was 52.3% in the D-VRd arm vs 34.8% in the VRd arm. The Food and Drug Administration (FDA) has approved Darzalex Faspro ® (daratumumab and ...

SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...